Review
[Mitotane in the treatment of adrenal carcinoma]
[Article in
Finnish]
Affiliations
- PMID: 21053521
Item in Clipboard
Review
[Mitotane in the treatment of adrenal carcinoma]
[Article in
Finnish]
Duodecim.
2010.
Abstract
Mitotane has been used for 50 years as the first-line drug in the treatment of disseminated adrenocortical carcinoma. It reduces local recurrence of the disease and development of metastases even after a seemingly total surgical removal of the tumor. The use of mitotane has been hampered by its copious adverse effects. Its use requires knowledge of the properties and biological effects of the product. Determination of plasma levels of mitotane will help in carrying out the treatment. The dosage can be optimized and the drug's adverse effects avoided by monitoring the plasma level.
Similar articles
-
Adjuvant mitotane treatment for adrenocortical carcinoma.N Engl J Med. 2007 Jun 7;356(23):2372-80. doi: 10.1056/NEJMoa063360. N Engl J Med. 2007. PMID: 17554118
-
Adjuvant mitotane in adrenocortical carcinoma.N Engl J Med. 2007 Sep 20;357(12):1257-8; author reply 1259. N Engl J Med. 2007. PMID: 17891838 No abstract available.
-
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.Eur J Endocrinol. 2013 Jul 29;169(3):263-70. doi: 10.1530/EJE-13-0242. Print 2013 Sep. Eur J Endocrinol. 2013. PMID: 23704714
-
Adjunctive treatment of adrenocortical carcinoma.Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):221-6. doi: 10.1097/MED.0b013e3282fdf4c0. Curr Opin Endocrinol Diabetes Obes. 2008. PMID: 18438168 Review.
-
Practical treatment using mitotane for adrenocortical carcinoma.Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):159-65. doi: 10.1097/MED.0000000000000056. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 24732405 Review.